REGULATORY
MHLW to Weigh All-Year Invitation for Sakigake Requests: Top Pharmacy Officer
The Ministry of Health, Labor and Welfare (MHLW) is set to consider having applications open all year long for its sakigake designation - the Japan equivalent of the US FDA’s Breakthrough Therapy status, but on a smaller scale thus far…
To read the full story
Related Article
- MHLW to Accept Sakigake Applications All Year Long under Amended PMD Law
August 27, 2020
- Fumi Yamamoto 1st Woman to Become MHLW’s Top Pharmacy Officer
December 23, 2019
REGULATORY
- Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
- Tepezza Price Cut Set at 5.5% under Japan’s CEA Scheme
August 6, 2026
- Dupixent Faces Fourth Re-Pricing under Japan’s SPA-SSS
August 6, 2026
- Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





